Castle Biosciences Inc (CSTL) Financial Statements

CSTL Financial Data

EBITDA$-2.52M

Revenue (TTM)$339.92M

Gross Profit (TTM)$264.74M

Gross Margin—

Operating Margin-12.44%

ROE-2.73%

ROA-2.22%

Debt/Equity0.08

Current Ratio5.26

FCF$28.37M

FCF Yield4.99%

Piotroski F-Score—

Rev/Share (TTM)$11.43

50-Day MA$24.12

200-Day MA$28.64

Shares Outstanding0.03B

CSTL Computed Insights

FCF$28.37M

FCF Growth Rate29.28%

EPS Growth (CAGR)50.00%

WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

CSTL Financial Statements & Data

Castle Biosciences Inc (CSTL) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Castle Biosciences Inc's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $339.92M. Gross profit (TTM) is $264.74M. EBITDA is $-2.52M. Earnings per share (EPS) is $-0.83. The P/E ratio is -44.32. Market capitalization is $568.76M.

Free cash flow (FCF) is $28.37M. FCF growth rate is 29.28%. EPS growth CAGR is 50.00%. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Castle Biosciences Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.